

PATENT  
Attorney's Docket Number: 7681.0010-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Prior Application: Art Unit: 1632  
Examiner: Couch

JC905 U.S. PTO  
09/650194  
08/29/00

SIR: This is a request for filing a

■ Continuation □ Continuation-in-Part □ Divisional Application under 37 C.F.R.  
§ 1.53(b) of pending prior application Serial No. 08/803,165 filed February 19, 1997  
of Keith Campbell et al. for UNACTIVATED OOCYTES AS CYTOPLAST  
RECIPIENTS FOR NUCLEAR TRANSFER.

1. ■ Enclosed is a complete copy of the prior application including the oath or Declaration and drawings, if any, as originally filed. I hereby verify that the attached papers are a true copy of prior application Serial No. 08/803,165 as originally filed on February 19, 1997.
2. □ Enclosed is a substitute specification under 37 C.F.R. § 1.125.
3. □ Cancel Claims \_\_\_\_\_.
4. ■ A Preliminary Amendment is enclosed.
5. ■ The filing fee is calculated on the basis of the claims existing in the prior application as amended at 3 and 4 above.

JC803 U.S. PTO  
08/29/00

09650194-082900

Basic Application Filing Fee					\$690	\$ 690.00
	Number of Claims		Basic	Extra Claims		
Total Claims	48	-	20	28	x \$18	504.00
Independent Claims	8	-	3	5	x \$78	390.00
■ Presentation of Multiple Dep. Claim(s)					+\$260	260.00
Subtotal						\$ 1844.00
Reduction by 1/2 if small entity						- 922.00
TOTAL APPLICATION FILING FEE						\$ 922.00

6. ■ A check in the amount of \$922.00 to cover the filing fee is enclosed.
7. ■ The Commissioner is hereby authorized to charge any fees which may be required including fees due under 37 C.F.R. § 1.16 and any other fees due under 37 C.F.R. § 1.17, or credit any overpayment during the pendency of this application to Deposit Account No. 06-0916.
8. ■ Amend the specification by inserting before the first line, the sentence:  
 --This is a ■ continuation of application Serial No. 08/803,165, filed February 19, 1997, which claims the benefit of PCT/GB96/02098, filed on August 30, 1996, and British application GB 9517779.6, filed on August 31, 1995, all of which are incorporated herein by reference.--
9. □ New formal drawings are enclosed.
10. ■ The prior application is assigned of record to: Roslin Institute (Edinburgh)
11. ■ Priority of application Serial Nos. PCT/GB96/02098, filed on August 30, 1996, and GB 9517779.6, filed on August 31, 1995 in Great Britain, is claimed under 35 U.S.C. § 119. A certified copy  
 □ is enclosed or ■ is on file in the prior application.
12. ■ A verified statement claiming small entity status  
 □ is enclosed or ■ is on file in the prior application.

006280-46705950

## LAW OFFICES

FINNEGAN, HENDERSON,  
 FARABOW, GARRETT,  
 & DUNNER, L.L.P.  
 1300 I STREET, N. W.  
 WASHINGTON, DC 20005  
 202-408-4000

13. ■ An associate power of attorney in the prior application is to at least one of the following: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P., Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,691; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Reilley, Reg. No. 27,932; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajefsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,165; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewris, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffen, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,738; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,984; Roger D. Taylor, Reg. 28,992; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,719; Christopher P. Isaac, Reg. No. 32,616; Bryan C. Diner, Reg. No. 32,409; M. Paul Barker, Reg. No. 32,013; Andrew Chanhon Sonu, Reg. No. 33,457; David S. Forman, Reg. No. 33,694; Vincent P. Kovalick, Reg. No. 32,867; James W. Edmondson, Reg. No. 33,871; Michael R. McGurk, Reg. No. 32,045; Joann M. Neth, Reg. No. 36,363; Gerson S. Panitch, Reg. No. 33,751; Cheri M. Taylor, Reg. No. 33,216; Charles E. Van Horn, Reg. No. 40,266; Linda A. Wadler, Reg. No. 33,218; Jeffrey A. Berkowitz, Reg. No. 36,743; Michael R. Kelly, Reg. No. 33, 921; James B. Monroe, Reg. No. 33,971; Doris Johnson Hines, Reg. No. 34,629; Allen R. Jensen, Reg. No. 28,224; Lori Ann Johnson, Reg. No. 34,498; and David A. Manspeizer, Reg. No. 37,540.

14. □ The power appears in the original declaration of the prior application.

006230 "46F05960

## LAW OFFICES


FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

15. ■ Since the power does not appear in the original declaration, a copy of the power in the prior application is enclosed.
16. ■ Please address all correspondence to FINNEGAN, HENDERSON, FARABOW, GARRETT and DUNNER, L.L.P., 1300 I Street, N.W., Washington, D.C. 20005-3315.
17. □ Recognize as associate attorney \_\_\_\_\_
18. □ Also enclosed is \_\_\_\_\_

PETITION FOR EXTENSION. If any extension of time is necessary for the filing of this application, including any extension in the parent application, Serial No. 08/803,165, filed February 19, 1997, for the purpose of maintaining copendency between the parent application and this application, and such extension has not otherwise been requested, such an extension is hereby requested, and the Commissioner is authorized to charge necessary fees for such an extension to our Deposit Account No. 06-0916. A duplicate copy of this paper is enclosed for use in charging the deposit account.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

By:   
Kenneth J. Meyers  
Reg. No. 25,146

Date: August 29, 2000

Tel: (202) 408-4033  
Fax: (202) 408-4400  
Email: meyersk@finnegan.com

Applicant or Patentee: Roslin Institute (Edinburgh) Attorney's Docket No.: 2980-003  
Serial or Patent No.: 08/803,165  
Filed or Issued: February 19, 1997  
For: UNACTIVATED OOCYTES AS CYTOPLAST RECIPIENTS FOR NUCLEAR TRANSFER

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37) CFR 1.9(f) and 1.27(d) - NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Roslin Institute (Edinburgh)

ADDRESS OF ORGANIZATION: Roslin, Midlothian EH25 9PS, Great Britain

TYPE OF ORGANIZATION:

- ☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION  
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) AND 501(c)(3))  
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA  
(Name of State: \_\_\_\_\_)  
(Citation of Statute: \_\_\_\_\_)  
☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) and 501(c)(3)) IF LOCATED IN THE UNITED STATES OF AMERICA  
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA  
(Name of State: \_\_\_\_\_)  
(Citation of Statute: \_\_\_\_\_)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled UNACTIVATED OOCYTES AS CYTOPLAST RECIPIENTS FOR NUCLEAR TRANSFER by inventor(s) Keith Henry Stockman Campbell and Ian Wilmut described in

- ☐ the specification filed herewith  
☒ application Serial No. 08/803,165, filed February 19, 1997.  
☐ patent no. , issued .

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or by a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
 )  
Campbell et al. )  
 )  
Serial No.: Unassigned )  
(Prior Appl. Ser. No. 08/803,165) ) Group Art Unit: Unassigned  
 )  
Filed: August 29, 2000 ) Examiner: Unassigned  
 )  
For: UNACTIVATED OOCYTES AS )  
CYTOPLAST RECIPIENTS FOR )  
NUCLEAR TRANSFER )

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

**PRELIMINARY AMENDMENT**

Prior to the examination of the above application, please amend this application  
as follows:

**IN THE CLAIMS:**

Please cancel claims 1-18.

Please add the following new claims:

--19. A method of cloning a cow by nuclear transfer comprising:

(i) inserting a nucleus of a cultured diploid bovine fibroblast in the G1 phase  
of the cell cycle into an unactivated, enucleated metaphase II-arrested bovine oocyte to  
reconstruct an embryo;

(ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;

(iii) activating the resultant reconstructed embryo;

(iv) culturing said activated, reconstructed embryo to blastocyst; and

(v) transferring said cultured, reconstructed embryo to a host cow such that the reconstructed embryo develops to term.

20. The method of claim 19, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

21. The method of claim 19 or 20, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

22. The method of claim 19 or 20, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

23. A method of cloning a bovine fetus by nuclear transfer comprising:

(i) inserting a nucleus of a cultured diploid bovine fibroblast in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested bovine oocyte to reconstruct an embryo;

(ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;

(iii) activating the resultant reconstructed embryo;

(iv) culturing said activated, reconstructed embryo to blastocyst; and

(v) transferring said cultured, reconstructed embryo to a host cow such that

the reconstructed embryo develops into a fetus.

24. The method of claim 23, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

25. The method of claim 23 or 24, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

26. The method of claim 23 or 24, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

27. A method of cloning a sheep by nuclear transfer comprising:

(i) inserting a nucleus of a cultured diploid ovine fibroblast in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested ovine oocyte to reconstruct an embryo;

(ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;

(iii) activating the resultant reconstructed embryo;

(iv) culturing said activated, reconstructed embryo to blastocyst; and

(v) transferring said cultured, reconstructed embryo to a host sheep such that the reconstructed embryo develops to term.

28. The method of claim 27, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

29. The method of claim 27 or 28, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.



30. The method of claim 27 or 28, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

31. A method of cloning a ovine fetus by nuclear transfer comprising:

(i) inserting a nucleus of a cultured diploid ovine fibroblast in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested ovine oocyte to reconstruct an embryo;

(ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;

(iii) activating the resultant reconstructed embryo;

(iv) culturing said activated, reconstructed embryo to blastocyst; and

(v) transferring said cultured, reconstructed embryo to a host sheep such that the reconstructed embryo develops into a fetus.

32. The method of claim 31, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

33. The method of claim 31 or 32, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

34. The method of claim 31 or 32, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

35. A method of cloning an non-human mammal by nuclear transfer comprising:

(i) inserting a nucleus of a cultured diploid non-human mammalian fibroblast

in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested non-human mammalian oocyte of the same species to reconstruct an embryo;

- (ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;
- (iii) activating the resultant reconstructed embryo;
- (iv) culturing said activated, reconstructed embryo to blastocyst; and
- (v) transferring said cultured, reconstructed embryo to a host non-human mammal of the same species such that the reconstructed embryo develops to term.

36. The method of claim 35, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

37. The method of claim 35 or 36, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

38. The method of claim 35 or 36, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

39. A method of cloning a non-human mammalian fetus by nuclear transfer comprising:

- (i) inserting a nucleus of a cultured diploid non-human mammalian fibroblast in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested non-human mammalian oocyte of the same species to reconstruct an embryo;
- (ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;

- (iii) activating the resultant reconstructed embryo;
- (iv) culturing said activated, reconstructed embryo to blastocyst; and
- (v) transferring said cultured, reconstructed embryo to a host non-human mammal of the same species such that the reconstructed embryo develops into a fetus.

40. The method of claim 39, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

41. The method of claim 39 or 40, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

42. The method of claim 39 or 40, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

43. A method of cloning a non-human mammal by nuclear transfer comprising:

- (i) inserting a nucleus of a cultured diploid non-human mammalian differentiated cell in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested non-human mammalian oocyte of the same species to reconstruct an embryo;
- (ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;
- (iii) activating the resultant reconstructed embryo;
- (iv) culturing said activated, reconstructed embryo to blastocyst; and
- (v) transferring said cultured, reconstructed embryo to a host non-human

mammal of the same species such that the reconstructed embryo develops to term.

44. The method of claim 43, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

45. The method of claim 43 or 44, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

46. The method of claim 43 or 44, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*.

47. A method of cloning a non-human mammalian fetus by nuclear transfer comprising:

- (i) inserting a nucleus of a cultured diploid non-human mammalian differentiated cell in the G1 phase of the cell cycle into an unactivated, enucleated metaphase II-arrested non-human mammalian oocyte of the same species to reconstruct an embryo;
- (ii) maintaining the reconstructed embryo without activation for a sufficient time to allow the reconstructed embryo to become capable of developing to term;
- (iii) activating the resultant reconstructed embryo;
- (iv) culturing said activated, reconstructed embryo to blastocyst; and
- (v) transferring said cultured, reconstructed embryo to a host non-human mammal of the same species such that the reconstructed embryo develops into a fetus.

48. The method of claim 47, wherein said step of activating the resultant reconstructed embryo comprises activating the embryo with a DC pulse.

49. The method of claim 47 or 48, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vitro*.

50. The method of claim 47 or 48, wherein said step of culturing said activated, reconstructed embryo to blastocyst is performed *in vivo*--

### REMARKS

Claims 1-18 have been canceled. Claims 19-50 are new and are fully supported by the specification. For example, claims 19-50 find support as follows:

<u>Claim</u>	<u>Support</u>
19, 23, 27, 31, 35, 39, 43, and 47	original claims 1, 3, 6, and 13 page 5, lines 1-28 page 7, lines 16-21 page 8, lines 9-22 and 29-33 page 9, line 7 page 10, 18-24 page 12, lines 22-28 page 17, lines 1-3 page 19, lines 17-28 pages 21-28
20, 24, 28, 32, 36, 40, 44, and 48	pages 13-14, bridging paragraph page 26, lines 11-12
21, 25, 29, 33, 37, 41, 45, and 49	page 17, lines 1-3 page 18, 5-16
22, 26, 30, 34, 38, 41, 46, and 50	page 17, lines 1-3 page 18, 5-16 page 27, lines 12-14.

No new matter enters by amendment. Upon amendment, claims 19-50 are

pending in this application.


Claims 19-50 may correspond substantially to the claims in U.S. Patent No. 5,945,577, issued August 31, 1999. Applicants are considering whether to seek an interference with this patent.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Date: August 29, 2000

By:   
Kenneth J. Meyers  
Reg. No. 25,146  
Tel: 202-408-4000  
Fax: 202-408-4400  
E-mail: [MEYERSK@finnegan.com](mailto:MEYERSK@finnegan.com)

006280 "46T05960

LAW OFFICES

FINNEGAN, HENDERSON,  
FARABOW, GARRETT,  
& DUNNER, L.L.P.  
1300 I STREET, N. W.  
WASHINGTON, DC 20005  
202-408-4000

UNACTIVATED OOCYTES AS CYTOPLAST RECIPIENTS  
FOR NUCLEAR TRANSFER

5 This invention relates to the generation of animals including but not being limited to genetically selected and/or modified animals, and to cells useful in their generation.

10 The reconstruction of mammalian embryos by the transfer of a donor nucleus to an enucleated oocyte or one cell zygote allows the production of genetically identical individuals. This has clear advantages for both research (i.e. as biological controls) and also in commercial applications (i.e. multiplication of genetically valuable  
15 livestock, uniformity of meat products, animal management).

Embryo reconstruction by nuclear transfer was first proposed (Spemann, *Embryonic Development and Induction*  
20 210-211 Hofner Publishing Co., New York (1938)) in order to answer the question of nuclear equivalence or 'do nuclei change during development?'. By transferring nuclei from increasingly advanced embryonic stages these experiments were designed to determine at which point  
25 nuclei became restricted in their developmental potential. Due to technical limitations and the unfortunate death of Spemann these studies were not completed until 1952, when it was demonstrated in the frog that certain nuclei could direct development to a  
30 sexually mature adult (Briggs and King, *Proc. Natl. Acad. Sci. USA* 38 455-461 (1952)). Their findings led to the current concept that equivalent totipotent nuclei from a single individual could, when transferred to an enucleated egg, give rise to "genetically identical"

00550194-082900

individuals. In the true sense of the meaning these individuals would not be clones as unknown cytoplasmic contributions in each may vary and also the absence of any chromosomal rearrangements would have to be demonstrated.

Since the demonstration of embryo cloning in amphibians, similar techniques have been applied to mammalian species. These techniques fall into two categories:

- 1) transfer of a donor nucleus to a matured metaphase II oocyte which has had its chromosomal DNA removed and
- 2) transfer of a donor nucleus to a fertilised one cell zygote which has had both pronuclei removed. In ungulates the former procedure has become the method of choice as no development has been reported using the latter other than when pronuclei are exchanged.

Transfer of the donor nucleus into the oocyte cytoplasm is generally achieved by inducing cell fusion. In ungulates fusion is induced by application of a DC electrical pulse across the contact/fusion plane of the couplet. The same pulse which induces cell fusion also activates the recipient oocyte. Following embryo reconstruction further development is dependent on a large number of factors including the ability of the nucleus to direct development i.e. totipotency, developmental competence of the recipient cytoplasm (i.e. oocyte maturation), oocyte activation, embryo culture (reviewed Campbell and Wilmut in *Vth World Congress on Genetics as Applied to Livestock* 20 180-187 (1994)).

In addition to the above we have shown that maintenance of correct ploidy during the first cell cycle of the reconstructed embryo is of major importance (Campbell

006280"46F05960



et al., *Biol. Reprod.* 49 933-942 (1993); Campbell et al., *Biol. Reprod.* 50 1385-1393 (1994)). During a single cell cycle all genomic DNA must be replicated once and only once prior to mitosis. If any of the DNA either fails to replicate or is replicated more than once then the ploidy of that nucleus at the time of mitosis will be incorrect. The mechanisms by which replication is restricted to a single round during each cell cycle are unclear, however, several lines of evidence have implicated that maintenance of an intact nuclear membrane is crucial to this control. The morphological events which occur in the donor nucleus after transfer into an enucleated metaphase II oocyte have been studied in a number of species including mouse (Czolowska et al., *J. Cell Sci.* 69 19-34 (1984)), rabbit (Collas and Robl, *Biol. Reprod.* 45 455-465 (1991)), pig (Prather et al., *J. Exp. Zool.* 225 355-358 (1990)), cow (Kanka et al., *Mol. Reprod. Dev.* 29 110-116 (1991)). Immediately upon fusion the donor nuclear envelope breaks down (NEBD), and the chromosomes prematurely condense (PCC). These effects are catalysed by a cytoplasmic activity termed maturation/mitosis/meiosis promoting factor (MPF). This activity is found in all mitotic and meiotic cells reaching a maximal activity at metaphase. Matured mammalian oocytes are arrested at metaphase of the 2nd meiotic division (metaphase II) and have high MPF activity. Upon fertilisation or activation MPF activity declines, the second meiotic division is completed and the second polar body extruded, the chromatin then decondenses and pronuclear formation occurs. In nuclear transfer embryos reconstructed when MPF levels are high NEBD and PCC occur; these events are followed, when MPF activity declines, by chromatin decondensation and nuclear reformation and subsequent DNA replication. In

reconstructed embryos correct ploidy can be maintained in one of two ways; firstly by transferring nuclei at a defined cell cycle stage, e.g. diploid nuclei of cells in G1, into metaphase II oocytes at the time of activation; or secondly by activating the recipient oocyte and transferring the donor nucleus after the disappearance of MPF activity. In sheep this latter approach has yielded an increase in the frequency of development to the blastocyst stage from 21% to 55% of reconstructed embryos when using blastomeres from 16 cell embryos as nuclear donors (Campbell et al., *Biol. Reprod.* 50 1385-1393 (1994)).

These improvements in the frequency of development of reconstructed embryos have as yet not addressed the question of nuclear reprogramming. During development certain genes become "imprinted" i.e. are altered such that they are no longer transcribed. Studies on imprinting have shown that this "imprinting" is removed during germ cell formation (i.e. reprogramming). One possibility is that this reprogramming is affected by exposure of the chromatin to cytoplasmic factors which are present in cells undergoing meiosis. This raises the question of how we may mimic this situation during the reconstruction of embryos by nuclear transfer in order to reprogram the developmental clock of the donor nucleus.

It has now been found that nuclear transfer into an oocyte arrested in metaphase II can give rise to a viable embryo if normal ploidy (i.e. diploidy) is maintained and if the embryo is not activated at the time of nuclear transfer. The delay in activation allows the nucleus to remain exposed to the recipient cytoplasm.

According to a first aspect of the present invention there is provided a method of reconstituting an animal embryo, the method comprising transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division without concomitantly activating the oocyte, keeping the nucleus exposed to the cytoplasm of the recipient for a period of time sufficient for the reconstituted embryo to become capable of giving rise to a live birth and subsequently activating the reconstituted embryo while maintaining correct ploidy. At this stage, the reconstituted embryo is a single cell.

In principle, the invention is applicable to all animals, including birds such as domestic fowl, amphibian species and fish species. In practice, however, it will be to non-human animals, especially non-human mammals, particularly placental mammals, that the greatest commercially useful applicability is presently envisaged. It is with ungulates, particularly economically important ungulates such as cattle, sheep, goats, water buffalo, camels and pigs that the invention is likely to be most useful, both as a means for cloning animals and as a means for generating transgenic animals. It should also be noted that the invention is also likely to be applicable to other economically important animal species such as, for example, horses, llamas or rodents, e.g. rats or mice, or rabbits.

The invention is equally applicable in the production of transgenic, as well as non-transgenic animals. Transgenic animals may be produced from genetically altered donor cells. The overall procedure has a number of advantages over conventional procedures for the production of

transgenic (i.e. genetically modified) animals which may be summarised as follows:

- (1) fewer recipients will be required;
- 5       (2) multiple syngeneic founders may be generated using clonal donor cells;
- (3) subtle genetic alteration by gene targeting is permitted;
- 10       (4) all animals produced from embryos prepared by the invention should transmit the relevant genetic modification through the germ line as each animal is derived from a single nucleus; in contrast, production of transgenic animals by pronuclear injection or chimerism after inclusion of modified stem cell populations by blastocyst injection produces a proportion of mosaic animals in which all cells do not contain the modification and may not transmit the modification through the germ line; and
- 15       (5) cells can be selected for the site of genetic modification (e.g. integration) prior to the generation of the whole animal.
- 20

It should be noted that the term "transgenic", in relation to animals, should not be taken to be limited to referring to animals containing in their germ line one or more genes from another species, although many transgenic animals will contain such a gene or genes. Rather, the term refers more broadly to any animal whose germ line has been the subject of technical intervention by recombinant DNA technology. So, for example, an animal in whose germ line an endogenous gene has been deleted, duplicated, activated or modified is a transgenic animal for the purposes of this invention as much as an animal

25

30

00550494 082900

to whose germ line an exogenous DNA sequence has been added.

In embodiments of the invention in which the animal is transgenic, the donor nucleus is genetically modified. The donor nucleus may contain one or more transgenes and the genetic modification may take place prior to nuclear transfer and embryo reconstitution. Although micro-injection, analogous to injection into the male or female pronucleus of a zygote, may be used as a method of genetic modification, the invention is not limited to that methodology: mass transformation or transfection techniques can also be used e.g. electroporation, viral transfection or lipofection.

In the method of the invention described above, a diploid nucleus is transferred from a donor into the enucleated recipient oocyte. Donors which are diploid at the time of transfer are necessary in order to maintain the correct ploidy of the reconstituted embryo; therefore donors may be either in the G1 phase or preferably, as is the subject of our co-pending PCT patent application No. PCT/GB96/02099 filed today (claiming priority from GB 9517780.4), in the G0 phase of the cell cycle.

The mitotic cell cycle has four distinct phases, G, S, G2 and M. The beginning event in the cell cycle, called *start*, takes place in the G1 phase and has a unique function. The decision or commitment to undergo another cell cycle is made at *start*. Once a cell has passed through *start*, it passes through the remainder of the G1 phase, which is the pre-DNA synthesis phase. The second stage, the S phase, is when DNA synthesis takes place. This is followed by the G2 phase, which is the period

between DNA synthesis and mitosis. Mitosis itself occurs at the M phase. Quiescent cells (which include cells in which quiescence has been induced as well as those cells which are naturally quiescent, such as certain fully differentiated cells) are generally regarded as not being in any of these four phases of the cycle; they are usually described as being in a G0 state, so as to indicate that they would not normally progress through the cycle. The nuclei of quiescent G0 cells, like the nuclei of G1 cells, have a diploid DNA content; both of such diploid nuclei can be used in the present invention.

Subject to the above, it is believed that there is no significant limitation on the cells that can be used in nuclear donors: fully or partially differentiated cells or undifferentiated cells can be used as can cells which are cultured *in vitro* or abstracted *ex vivo*. The only limitation is that the donor cells have normal DNA content and be karyotypically normal. A preferred source of cells is disclosed in our co-pending PCT patent application No. PCT/GB95/02095, published as WO 96/07732. It is believed that all such normal cells contain all of the genetic information required for the production of an adult animal. The present invention allows this information to be provided to the developing embryo by altering chromatin structure such that the genetic material can re-direct development.

Recipient cells useful in the invention are enucleated oocytes which are arrested in the metaphase of the second meiotic division. In most vertebrates, oocyte maturation proceeds *in vivo* to this fairly late stage of the egg maturation process and then arrests. At ovulation, the arrested oocyte is released from the ovary (and, if

fertilisation occurs, the oocyte is naturally stimulated to complete meiosis). In the practice of the invention, oocytes can be matured either *in vitro* or *in vivo* and are collected on appearance of the 1st polar body or as soon as possible after ovulation, respectively.

It is preferred that the recipient be enucleate. While it has been generally assumed that enucleation of recipient oocytes in nuclear transfer procedures is essential, there is no published experimental confirmation of this judgement. The original procedure described for ungulates involved splitting the cell into two halves, one of which was likely to be enucleated (Willadsen *Nature* 320 (6) 63-65 (1986)). This procedure has the disadvantage that the other unknown half will still have the metaphase apparatus and that the reduction in volume of the cytoplasm is believed to accelerate the pattern of differentiation of the new embryo (Eviskov *et al.*, *Development* 109 322-328 (1990)).

More recently, different procedures have been used in attempts to remove the chromosomes with a minimum of cytoplasm. Aspiration of the first polar body and neighbouring cytoplasm was found to remove the metaphase II apparatus in 67% of sheep oocytes (Smith & Wilmut *Biol. Reprod.* 40 1027-1035 (1989)). Only with the use of DNA-specific fluorochrome (Hoechst 33342) was a method provided by which enucleation would be guaranteed with the minimum reduction in cytoplasmic volume (Tsunoda *et al.*, *J. Reprod. Fertil.* 82 173 (1988)). In livestock species, this is probably the method of routine use at present (Prather & First *J. Reprod. Fertil. Suppl.* 41 125 (1990), Westhusin *et al.*, *Biol. Reprod. (Suppl.)* 42 176 (1990)).

There have been very few reports of non-invasive approaches to enucleation in mammals, whereas in amphibians, irradiation with ultraviolet light is used as a routine procedure (Gurdon *Q. J. Microsc. Soc.* 101 299-311 (1960)). There are no detailed reports of the use of this approach in mammals, although during the use of DNA-specific fluorochrome it was noted that exposure of mouse oocytes to ultraviolet light for more than 30 seconds reduced the developmental potential of the cell (Tsunoda *et al.*, *J. Reprod. Fertil.* 82 173 (1988)).

As described above enucleation may be achieved physically, by actual removal of the nucleus, pro-nuclei or metaphase plate (depending on the recipient cell), or functionally, such as by the application of ultraviolet radiation or another enucleating influence.

After enucleation, the donor nucleus is introduced either by fusion to donor cells under conditions which do not induce oocyte activation or by injection under non-activating conditions. In order to maintain the correct ploidy of the reconstructed embryo the donor nucleus must be diploid (i.e. in the G0 or G1 phase of the cell cycle) at the time of fusion.

Once suitable donor and recipient cells have been prepared, it is necessary for the nucleus of the former to be transferred to the latter. Most conveniently, nuclear transfer is effected by fusion. Activation should not take place at the time of fusion.

Three established methods which have been used to induce fusion are:

006280"46F05960



- (1) exposure of cells to fusion-promoting chemicals, such as polyethylene glycol;
- (2) the use of inactivated virus, such as Sendai virus; and
- 5 (3) the use of electrical stimulation.

0066280"46F0960

Exposure of cells to fusion-promoting chemicals such as polyethylene glycol or other glycols is a routine procedure for the fusion of somatic cells, but it has not  
10 been widely used with embryos. As polyethylene glycol is toxic it is necessary to expose the cells for a minimum period and the need to be able to remove the chemical quickly may necessitate the removal of the zona pellucida (Kanka et al., *Mol. Reprod. Dev.* 29 110-116 (1991)). In  
15 experiments with mouse embryos, inactivated Sendai virus provides an efficient means for the fusion of cells from cleavage-stage embryos (Graham *Wistar Inst. Symp. Monogr.* 9 19 (1969)), with the additional experimental advantage that activation is not induced. In ungulates, fusion is  
20 commonly achieved by the same electrical stimulation that is used to induce parthogenetic activation (Willadsen *Nature* 320 (6) 63-65 (1986), Prather et al., *Biol. Reprod.* 37 859-866 (1987)). In these species, Sendai virus induces fusion in a proportion of cases, but is not  
25 sufficiently reliable for routine application (Willadsen *Nature* 320 (6) 63-65 (1986)).

While cell-cell fusion is a preferred method of effecting nuclear transfer, it is not the only method that can be  
30 used. Other suitable techniques include microinjection (Ritchie and Campbell, *J. Reproduction and Fertility Abstract Series No. 15*, p60).

In a preferred embodiment of the invention, fusion of the oocyte karyoplast couplet is accomplished in the absence of activation by electropulsing in 0.3M mannitol solution or 0.27M sucrose solution; alternatively the nucleus may be introduced by injection in a calcium free medium. The age of the oocytes at the time of fusion/injection and the absence of calcium ions from the fusion/injection medium prevent activation of the recipient oocyte.

In practice, it is best to enucleate and conduct the transfer s soon as possible after the oocyte reaches metaphase II. The time that this will be post onset of maturation (*in vitro*) or hormone treatment (*in vivo*) will depend on the species. For cattle or sheep, nuclear transfer should preferably take place within 24 hours; for pigs, within 48 hours; mice, within 12 hours; and rabbits within 20-24 hours. although transfer can take place later, it becomes progressively more difficult to achieve as the oocyte ages. High MPF activity is desirable.

Subsequently, the fused reconstructed embryo, which is generally returned to the maturation medium, is maintained without being activated so that the donor nucleus is exposed to the recipient cytoplasm for a period of time sufficient to allow the reconstructed embryo to become capable, eventually, of giving rise to a live birth (preferably of a fertile offspring).

The optimum period of time before activation varies from species to species and can readily be determined by experimentation. For cattle, a period of from 6 to 20 hours is appropriate. The time period should probably not be less than that which will allow chromosome

formation, and it should not be so long either that the couplet activates spontaneously or, in extreme cases that it dies.

5 When it is time for activation, any conventional or other  
suitable activation protocol can be used. Recent  
experiments have shown that the requirements for  
parthogenetic activation are more complicated than had  
10 been imagined. It had been assumed that activation is an  
all-or-none phenomenon and that the large number of  
treatments able to induce formation of a pronucleus were  
all causing "activation". However, exposure of rabbit  
oocytes to repeated electrical pulses revealed that only  
15 selection of an appropriate series of pulses and control  
of the  $\text{Ca}^{2+}$  was able to promote development of diploidized  
oocytes to mid-gestation (Ozil *Development* 109 117-127  
(1990)). During fertilization there are repeated,  
transient increases in intracellular calcium  
20 concentration (Cutbertson & Cobbold *Nature* 316 541-542  
(1985)) and electrical pulses are believed to cause  
analogous increases in calcium concentration. There is  
evidence that the pattern of calcium transients varies  
with species and it can be anticipated that the optimal  
25 pattern of electrical pulses will vary in a similar  
manner. The interval between pulses in the rabbit is  
approximately 4 minutes (Ozil *Development* 109 117-127  
(1990)), and in the mouse 10 to 20 minutes (Cutbertson &  
Cobbold *Nature* 316 541-542 (1985)), while there are  
30 preliminary observations in the cow that the interval is  
approximately 20 to 30 minutes (Robl et al., in *Symposium  
on Cloning Mammals by Nuclear Transplantation* (Seidel  
ed.), Colorado State University, 24-27 (1992)). In most  
published experiments activation was induced with a  
single electrical pulse, but new observations suggest

00650194-082900

that the proportion of reconstituted embryos that develop is increased by exposure to several pulses (Collas & Robl *Biol. Reprod.* 43 877-884 (1990)). In any individual case, routine adjustments may be made to optimise the number of pulses, the field strength and duration of the pulses and the calcium concentration of the medium.

In the practice of the invention, correct ploidy must be maintained during activation. It is desirable to inhibit or stabilise microtubule polymerisation in order to prevent the production of multiple pronuclei, thereby to maintain correct ploidy. This can be achieved by the application of a microtubule inhibitor such as nocodazole at an effective concentration (such as about 5µg/ml). Colchicine and colcemid are other microtubule inhibitors. Alternatively, a microtubule stabiliser, such as, for example, taxol could be used.

The molecular component of microtubules (tubulin) is in a state of dynamic equilibrium between the polymerised and non-polymerised states. Microtubule inhibitors such as nocodazole prevent the addition of tubulin molecules to microtubules, thereby disturbing the equilibrium and leading to microtubule depolymerisation and destruction of the spindle. It is preferred to add the microtubule inhibitor a sufficient time before activation to ensure complete, or almost complete, depolymerisation of the microtubules. Twenty to thirty minutes is likely to be sufficient in most cases. A microtubule stabiliser such as taxol prevents the breakdown of the spindle and may also therefore prevent the production of multiple pronuclei. Use of a microtubule stabiliser is preferably under similar conditions to those used for microtubule inhibitors.

The microtubule inhibitor or stabiliser should remain present after activation until pronuclei formation. It should be removed thereafter, and in any event before the first division takes place.

5

In a preferred embodiment of the invention at 30-42 hours post onset of maturation (bovine and ovine, i.e. 6-18 hours post nuclear transfer) the reconstructed oocytes are placed into medium containing nocodazole (5 $\mu$ g/ml) and activated using conventional protocols. Incubation in nocodazole may be continued for 4-6 hours following the activation stimulus (dependent upon species and oocyte age).

10

According to a second aspect of the invention, there is provided a viable reconstituted animal embryo prepared by a method as described previously.

15

According to a third aspect of the invention, there is provided a method of preparing an animal, the method comprising:

20

- (a) reconstituting an animal embryo as described above; and
- (b) causing an animal to develop to term from the embryo; and
- (c) optionally, breeding from the animal so formed.

25

Step (a) has been described in depth above.

30

The second step, step (b) in the method of this aspect of the invention is to cause an animal to develop to term from the embryo. This may be done directly or indirectly. In direct development, the reconstituted embryo from step

(a) is simply allowed to develop without further intervention beyond any that may be necessary to allow the development to take place. In indirect development, however, the embryo may be further manipulated before full development takes place. For example, the embryo may be split and the cells clonally expanded, for the purpose of improving yield.

Alternatively or additionally, it may be possible for increased yields of viable embryos to be achieved by means of the present invention by clonal expansion of donors and/or if use is made of the process of serial (nuclear) transfer. A limitation in the presently achieved rate of blastocyst formation may be due to the fact that a majority of the embryos do not "reprogram" (although an acceptable number do). If this is the case, then the rate may be enhanced as follows. Each embryo that does develop itself can be used as a nuclear donor at the 32-64 cell stage; alternatively, inner cell mass cells can be used at the blastocyst stage. If these embryos do indeed reflect those which have reprogrammed gene expression and those nuclei are in fact reprogrammed (as seems likely), then each developing embryo may be multiplied in this way by the efficiency of the nuclear transfer process. The degree of enhancement likely to be achieved depends upon the cell type. In sheep, it is readily possible to obtain 55% blastocyst stage embryos by transfer of a single blastomere from a 16 cell embryo to a preactivated "Universal Recipient" oocyte. So it is reasonable to hypothesise that each embryo developed from a single cell could give rise to eight at the 16 cell stage. Although these figures are just a rough guide, it is clear that at later developmental stages the extent of benefit would depend on the efficiency of the process at that stage.

Aside from the issue of yield-improving expediciencies, the reconstituted embryo may be cultured, *in vivo* or *in vitro* to blastocyst.

5 Experience suggests that embryos derived by nuclear transfer are different from normal embryos and sometimes benefit from or even require culture conditions *in vivo* other than those in which embryos are usually cultured (at least *in vivo*). The reason for this is not known.

10 In routine multiplication of bovine embryos, reconstituted embryos (many of them at once) have been cultured in sheep oviducts for 5 to 6 days (as described by Willadsen, In Mammalian Egg Transfer (Adams, E.E., ed.) 185 CRC Press, Boca Raton, Florida (1982)). In the

15 practice of the present invention, though, in order to protect the embryo it should preferably be embedded in a protective medium such as agar before transfer and then dissected from the agar after recovery from the temporary recipient. The function of the protective agar or other

20 medium is twofold: first, it acts as a structural aid for the embryo by holding the zona pellucida together; and secondly it acts as barrier to cells of the recipient animal's immune system. Although this approach increases the proportion of embryos that form blastocysts, there is

25 the disadvantage that a number of embryos may be lost.

If *in vitro* conditions are used, those routinely employed in the art are quite acceptable.

30 At the blastocyst stage, the embryo may be screened for suitability for development to term. Typically, this will be done where the embryo is transgenic and screening and selection for stable integrants has been carried out. Screening for non-transgenic genetic markers may also be

carried out at this stage. However, because the method of the invention allows for screening of donors at an earlier stage, that will generally be preferred.

5 After screening, if screening has taken place, the blastocyst embryo is allowed to develop to term. This will generally be *in vivo*. If development up to blastocyst has taken place *in vitro*, then transfer into the final recipient animal takes place at this stage. If  
10 blastocyst development has taken place *in vivo*, although in principle the blastocyst can be allowed to develop to term in the pre-blastocyst host, in practice the blastocyst will usually be removed from the (temporary) pre-blastocyst recipient and, after dissection from the  
15 protective medium, will be transferred to the (permanent) post-blastocyst recipient.

In optional step (c) of this aspect of the invention, animals may be bred from the animal prepared by the  
20 preceding steps. In this way, an animal may be used to establish a herd or flock of animals having the desired genetic characteristic(s).

Animals produced by transfer of nuclei from a source of  
25 genetically identical cells share the same nucleus, but are not strictly identical as they are derived from different oocytes. The significance of this different origin is not clear, but may affect commercial traits. Recent analyses of the mitochondrial DNA of dairy cattle  
30 in the Iowa State University Breeding Herd revealed associated with milk and reproductive performance (Freeman & Beitz, In Symposium on Cloning Mammals by Nuclear Transplantation (Seidel, G. E. Jr., ed.) 17-20, Colorado State University, Colorado (1992)). It remains

00650194 "082900



to be confirmed that similar effects are present throughout the cattle population and to consider whether it is possible or necessary in specific situations to consider the selection of oocytes. In the area of cattle breeding the ability to produce large numbers of embryos from donors of high genetic merit may have considerable potential value in disseminating genetic improvement through the national herd. The scale of application will depend upon the cost of each embryo and the proportion of transferred embryos able to develop to term.

By way of illustration and summary, the following scheme sets out a typical process by which transgenic and non-transgenic animals may be prepared. The process can be regarded as involving five steps:

- (1) isolation of diploid donor cells;
- (2) optionally, transgenesis, for example by transfection with suitable constructs, with or without selectable markers;
- (2a) optionally screen and select for stable integrants - skip for micro-injection;
- (3) embryo reconstitution by nuclear transfer;
- (4) culture, *in vivo* or *in vitro*, to blastocyst;
- (4a) optionally screen and select for stable integrants - omit if done at 2a - or other desired characteristics;
- (5) transfer if necessary to final recipient.

This protocol has a number of advantages over previously published methods of nuclear transfer:

- 1) The chromatin of the donor nucleus can be exposed to the meiotic cytoplasm of the recipient oocyte in the

006280"46T0560

absence of activation for appropriate periods of time. This may increase the "reprogramming" of the donor nucleus by altering the chromatin structure.

5        2)    Correct ploidy of the reconstructed embryo is maintained when G0/G1 nuclei are transferred.

10       3)    Previous studies have shown that activation responsiveness of bovine/ovine oocytes increases with age. One problem which has previously been observed is that in unenucleated aged oocytes duplication of the meiotic spindle pole bodies occurs and multipolar spindles are observed. However, we report that in embryos reconstructed and maintained with high MPF levels  
15       although nuclear envelope breakdown and chromatin condensation occur no organised spindle is observed. The prematurely condensed chromosomes remain in a tight bunch, therefore we can take advantage of the ageing process and increase the activation response of the  
20       reconstructed oocyte without adversely affecting the ploidy of the reconstructed embryo.

25       According to a fourth aspect of the invention, there is provided an animal prepared as described above.

Preferred features of each aspect of the invention are as for each other aspect, *mutatis mutandis*.

30       The invention will now be described by reference to the accompanying Examples which are provided for the purposes of illustration and are not to be construed as being limiting on the present invention. In the following description, reference is made to the accompanying drawing, in which:

FIGURE 1 shows the rate of maturation of bovine oocytes *in vitro*.

Example 1: "MAGIC" Procedure using Bovine Oocytes

5 Recipient oocytes the subject of this experimental procedure are designated MAGIC (Metaphase Arrested G1/G0 Accepting Cytoplasm) Recipients.

10 The nuclear and cytoplasmic events during *in vitro* oocyte maturation were studied. In addition the roles of fusion and activation in embryos reconstructed at different ages were also investigated. The studies have shown that oocyte maturation is asynchronous; however, a population of matured oocytes can be morphologically selected at 18 hours (Figure 1).

Morphological selection of oocytes

15 In Figure 1 ovaries were obtained from a local abattoir and maintained at 28-32°C during transport to the laboratory. Cumulus oocyte complexes (COC's) were aspirated from follicles 3-10mm in diameter using a hypodermic needle (1.2mm internal diameter) and placed into sterile plastic universal containers. The universal containers were placed into a warmed chamber (35°C) and the follicular material allowed to settle for 10-15 minutes before pouring off three quarters of the supernatant. The remaining follicular material was diluted with an equal volume of dissection medium (TCM 199 with Earles salts (Gibco), 75.0 mg/l kanamycin, 20 30.0mM Hepes, pH 7.4, osmolarity 280 mOsmols/Kg H<sub>2</sub>O) supplemented with 10% bovine serum, transferred into an 85mm petri dish and searched for COC's under a dissecting microscope.

006280 "45705950

Complexes with at least 2-3 compact layers of cumulus cells were selected washed three times in dissection medium and transferred into maturation medium (TC medium 199 with Earles salts (Gibco), 75mg/l kanamycin, 30.0mM Hepes, 7.69mM NaHCO<sub>3</sub>, pH 7.8, osmolarity 280 mOsmols/Kg H<sub>2</sub>O) supplemented with 10% bovine serum and 1x10<sup>6</sup> granulosa cells/ml and cultured on a rocking table at 39°C in an atmosphere of 5% CO<sub>2</sub> in air. Oocytes were removed from the maturation dish and wet mounted on ethanol cleaned glass slides under coverslips which were attached using a mixture of 5% petroleum jelly 95% wax. Mounted embryos were then fixed for 24 hours in freshly prepared methanol: glacial acetic acid (3:1), stained with 45% aceto-orcein (Sigma) and examined by phase contrast and DIC microscopy using a Nikon Microphot-SA, the graph in Figure 1 shows the percentage of oocytes at MII and those with a visible polar body.

#### Activation of bovine follicular oocytes

If maturation is then continued until 24 hours these oocytes activate at a very low rate (24%) in mannitol containing calcium (Table 1a). However, removal of calcium and magnesium from the electropulsing medium prevents any activation.

Table 1a shows activation of bovine follicular oocytes matured *in vitro* for different periods. Oocytes were removed from the maturation medium, washed once in activation medium, placed into the activation chamber and given a single electrical pulse of 1.25kV/cm for 80μs.

Table 1a

No. of oocytes (N)	Hours post onset of maturation (hpm) [age (hrs)]	Pronuclear formation (% activation)
73	24	24.6
99	30	84.8
55	45	92.7*

\*many 2 or more pronuclei

#### Activation response of sham enucleated bovine oocytes

Table 1b shows activation response of *in vitro* matured bovine oocytes sham enucleated at approximately 22 hours post onset of maturation (hpm). Oocytes were treated exactly as for enucleation, a small volume of cytoplasm was aspirated not containing the metaphase plate. After manipulation the oocytes were given a single DC pulse of 1.25 KV/cm and returned to the maturation medium, at 30 hpm and 42 hpm groups of oocytes were mounted, fixed and stained with aceto-orcein. The results show the number of oocytes at each time point from five individual experiments as the number of cells having pronuclei with respect to the total number of cells.

Table 1b

EXPERIMENT	No. cells having pronuclei/ Total no. of cells	No. cells having pronuclei/ Total no. of cells
	30 hpm	42 hpm
1	1/8	-
2	0/24	0/30
3	0/21	0/22
4	0/27	0/25
5	0/19	0/1

hpm = hours post onset of maturation

### Pronuclear formation in enucleated oocytes

Table 2 shows pronuclear formation in enucleated oocytes fused to primary bovine fibroblasts (24 hpm) and subsequently activated (42hpm). The results represent five separate experiments. Oocytes were divided into two groups, group A were incubated in nocodazole for 1 hour prior to activation and for 6 hours following activation. Group B were not treated with nocodazole. Activated oocytes were fixed and stained with aceto-orcein 12 hours post activation. The number of pronuclei (PN) in each parthenote was then scored under phase contrast. The results are expressed as the percentage of activated oocytes containing 1 or more pronuclei.

Table 2

	TOTAL	1 PN	2 PN	3 PN	4 PN	>4 PN
GROUP A	52	100	0	0	0	0
GROUP B	33	45.2	25.8	16.1	3.2	9.7

The absence of an organised spindle and the absence of a polar body suggests that in order to maintain ploidy in the reconstructed embryo then only a diploid i.e. G0/G1 nucleus should be transferred into this cytoplasmic situation. Incubation of activated oocytes in the presence of the microtubule inhibitor nocodazole for 5 hours, 1 hour prior to and following the activation stimulus prevents the formation of micronuclei (Table 2) and thus when the donor nucleus is in the G0/G1 phase of the cell cycle the correct ploidy of the reconstructed embryo is maintained.

### Results

These results show that:

i) these oocytes can be enucleated at 18 hours post onset of maturation (Figure 1);

ii) enucleated oocytes can be fused to donor blastomeres/cells in either 0.3M mannitol or 0.27M sucrose alternatively the donor the cells or nuclei can be injected in calcium free medium in the absence of any activation response;

iii) reconstructed embryos or enucleated pulsed oocytes can be cultured in maturation medium and do not undergo spontaneous activation;

iv) the transferred nucleus is seen to undergo nuclear envelope breakdown (NEBD) and chromosome condensation. No organised meiotic/mitotic spindle is observed regardless of the cell cycle stage of the transferred nucleus;

v) such manipulated couplets will activate at 30 hours and 42 hours with a frequency equal to unmanipulated control oocytes;

vi) no polar body is observed following subsequent activation, regardless of the cell cycle stage of the transferred nucleus;

viii) upon subsequent activation 1-5 micronuclei are formed per reconstructed zygote (Table 2).

#### Reconstruction of bovine embryos using "MAGIC" procedure

In preliminary experiments this technique has been applied to the reconstruction of bovine embryos using primary fibroblasts synchronised in the G0 phase of the

006280"46T05950

cell cycle by serum starvation for five days. The results are summarised in Table 3.

Table 3 shows development of bovine embryos reconstructed by nuclear transfer of serum starved (G0) bovine primary fibroblasts into enucleated unactivated MII oocytes. Embryos were reconstructed at 24 hpm and the fused couplets activated at 42 hpm. Fused couplets were incubated in nocodazole (5 $\mu$ g/ml) in M2 medium for 1 hour prior to activation and 5 hours post activation. Couplets were activated with a single DC pulse of 1.25 KV/cm for 80 $\mu$ sec.

Table 3

EXPERIMENT NUMBER	NUMBER OF BLASTOCYSTS/ TOTAL NUMBER OF FUSED COUPLETS	% BLASTOCYSTS
1	1/30	3.3
2	4/31	12.9

Example 2: "MAGIC" Procedure using Ovine Oocytes

Similar observations to those in Example 1 have also been made in ovine oocytes which have been matured *in vivo*. Freshly ovulated oocytes can be retrieved by flushing from the oviducts of superstimulated ewes 24 hours after prostaglandin treatment. The use of calcium magnesium free PBS/1.0% FCS as a flushing medium prevents oocyte activation. Oocytes can be enucleated in calcium free medium and donor cells introduced as above in the absence of activation. No organised spindle is observed, multiple nuclei are formed upon subsequent activation and this may be suppressed by nocodazole treatment.



### Results

In preliminary experiments in sheep, a single pregnancy has resulted in the birth of a single live lamb. The results are summarised in Tables 4 and 5.

Table 4 shows development of ovine embryos reconstructed by transfer of an embryo derived established cell line to unactivated enucleated *in vivo* matured ovine oocytes. Oocytes were obtained from superstimulated Scottish blackface ewes, the cell line was established from the embryonic disc of a day 9 embryo obtained from a Welsh mountain ewe. Reconstructed embryos were cultured in the ligated oviduct of a temporary recipient ewe for 6 days, recovered and assessed for development.

Table 4

DATE OF NUCLEAR TRANSFER	PASSAGE NUMBER	NUMBER OF MORULA, BLA STOCYSTS / TOTAL NUMBER
17.1.95	6	4/28
19.1.95	7	1/10
31.1.95	13	0/2
2.2.95	13	0/14
7.2.95	11	1/9
9.2.95	11	1/2
14.2.95	12	
16.2.95	13	3/13
TOTAL		10/78 (12.8%)

Table 5 shows induction of pregnancy following transfer of all morula/blastocyst stage reconstructed embryos to the uterine horn of synchronised final recipient blackface ewes. The table shows the total number of embryos from each group transferred the frequency of pregnancy in terms of ewes and embryos, in the majority of cases 2 embryos were transferred to each ewe. A single twin pregnancy was established which resulted in the birth of a single live lamb.

Table 5

PASSAGE NUMBER	"MAGIC"
P6	4
P7	1
P11	2
P12	0
P13	3
TOTAL MOR/BL	10
TOTAL NUMBER EWES	6
PREGNANT EWES %	1 (16.7)
FOETUSES/ TOTAL TRANSFERRED (%)	2/10 (20.0)

CLAIMS

1. A method of reconstituting an animal embryo, the process comprising transferring a diploid nucleus into an oocyte which is arrested in the metaphase of the second meiotic division without concomitantly activating the oocyte, keeping the nucleus exposed to the cytoplasm of the recipient for a period of time sufficient for the embryo to become capable of giving rise to a live birth and subsequently activating the reconstituted embryo while maintaining correct ploidy.
2. A method as claimed in claim 1, in which the animal is an ungulate species.
3. A method as claimed in claim 2, in which the animal is a cow or bull, pig, goat, sheep, camel or water buffalo.
4. A method as claimed in any one of claims 1 to 3, in which the donor nucleus is genetically modified.
5. A method as claimed in any one of claims 1 to 4, wherein the diploid nucleus is donated by a quiescent cell.
6. A method as claimed in any one of claims 1 to 5, wherein the recipient oocyte is enucleate.
7. A method as claimed in any one of claims 1 to 6, wherein nuclear transfer is achieved by cell fusion.
8. A method as claimed in any one of claims 1 to 7, wherein the animal is a cow or bull and wherein the donor

006280"46T05950

nucleus is kept exposed to the recipient cytoplasm for a period of from 6 to 20 hours prior to activation.

5 9. A method as claimed in any one of claims 1 to 8, wherein correct ploidy is maintained during activation by microtubule inhibition.

10 10. A method as claimed in claim 9, wherein microtubule inhibition is achieved by the application of nocodazole.

11 11. A method as claimed in any one of claims 1 to 8, wherein correct ploidy is maintained during activation by microtubule stabilisation.

15 12. A method as claimed in claim 11, wherein microtubule stabilisation is achieved by the application of taxol.

20 13. A method of preparing an animal, the method comprising:

- 25 (a) reconstituting an animal embryo as claimed in any preceding claim;  
(b) causing an animal to develop to term from the embryo; and  
(c) optionally, breeding from the animal so formed.

30 14. A method as claimed in claim 13, wherein the animal embryo is further manipulated prior to full development of the embryo.

15. A method as claimed in claim 14, wherein more than one animal is derived from the embryo.

00650194-032500

16. A reconstituted animal embryo which is capable of giving rise to a live birth and is prepared by a method as claimed in any one of claims 1 to 12.

5 17. An animal prepared by a method as claimed in any one of claims 13 to 15.

18. An animal developed from an embryo as claimed in claim 16.

10

006280 46 F05960

ABSTRACT  
UNACTIVATED OOCYTES AS CYTOPLAST RECIPIENTS  
FOR NUCLEAR TRANSFER

5       A method of reconstituting an animal embryo involves  
transferring a diploid nucleus into an oocyte which is  
arrested in the metaphase of the second meiotic division.  
The oocyte is not activated at the time of transfer, so  
that the donor nucleus is kept exposed to the recipient  
10       cytoplasm for a period of time. The diploid nucleus can  
be donated by a cell in either the G0 or G1 phase of the  
cell cycle at the time of transfer. Subsequently, the  
reconstituted embryo is activated. Correct ploidy is  
maintained during activation, for example, by incubating  
15       the reconstituted embryo in the presence of a microtubule  
inhibitor such as nocodazole. The reconstituted embryo  
may then give rise to one or more live animal births.  
The invention is useful in the production of transgenic  
animals as well as non-transgenics of high genetic merit.

006280-46105960

## **DECLARATION AND POWER OF ATTORNEY FOR APPLICATION UNDER 35 USC 111(a)**

As a below named inventor, I hereby declare that:

My residence, post office and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter claimed and for which a patent is sought on the invention entitled UNACTIVATED OOCYTES AS CYTOPLAST RECIPIENTS FOR NUCLEAR TRANSFER, the specification of which ☐ is attached hereto ☒ was filed on February 19, 1997 as Application Serial No. 08/803,165 and was amended on (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 or Section 365 of any foreign and/or International (PCT) application(s) for patent or inventor's certificate listed below, and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

**Prior Foreign Application(s):**

<u>Number</u>	<u>Country</u>	<u>Day/Month/Year filed</u>	<u>Priority Claimed</u>	
			<u>Yes</u>	<u>No</u>
PCT/GB96/02098	Great Britain	August 30, 1996	X	
GB 9517779.6	Great Britain	August 31, 1995	X	

I hereby claim the benefit under Title 35, United States Code, Section 120 or 365 of any United States and/or International (PCT) application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or International (PCT) filing date of this application:

**Prior U. S. Application(s):**

<u>Serial No.</u>	<u>Filing Date</u>	<u>Status: Patented, Pending, Abandoned</u>
PCT/GB96/02098	August 30, 1996	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorney(s) and/or agent(s): Allan M. Lowe, Reg. No. 19,641; Robert L. Price, Reg. No. 22,685; Stephen A. Becker, Reg. No. 26,527; Robert E. LeBlanc, Reg. No. 17,219; Israel Gopstein, Reg. No. 27,333; Benjamin J. Hauptman, Reg. No. 29,310; Kenneth E. Krosin, Reg. No. 25,735; Frank P. Presta, Reg. No. 19,828; Gilberto M. Villacorta, Reg. No. 34,038; Gene Z. Rubinson, Reg. No. 33,351; Chittaranjan N. Nirmel, Reg. No. 30,408; Keith E. George, Reg. No. 34,111; Christopher W. Brody, Reg. No. 33,613; Arthur J. Steiner, Reg. No. 26,106; Edward J. Wise, Reg. No. 34,523; Alfred A. Stadnicki, Reg. No. 30,226; David L. Stewart, Reg. No. 37,578; John A. Hankins, Reg. No. 32,029; Brian D. Hickman, Reg. No. 35,894; Demetra J. Mills, Reg. No. 34,506; Alexander Yampolsky, Reg. No. 36,324; Timothy R. DeWitt, Reg. No. 35,857; William H. Beha, Reg. No. 38,038; Irah H. Donner, Reg. No. 35,120; Eric J. Kraus, Reg. No. 36,190; Leon R. Turkevich, Reg. No. 34,035; Michael E. McCabe, Jr., Reg. No. 37,182; Edward A. Becker, Reg. No. 37,777; Kenneth M. Berner, Reg. No. 37,093; James H. Meadows, Reg. No. 33,965; Stephen C. Carlson, Reg. No. 39,929; Michael G. Gilman, Reg. No. 19,114; Glenn Snyder, Reg. No. P41,428; Thomas A. Jolly, Reg. No. 30,241 and Keith J. Townsend, Reg. No. 40,358, all of

LOWE PRICE LEBLANC & BECKER  
99 Canal Center Plaza, Suite 300  
Alexandria, Virginia 22314

with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and all future correspondence should be addressed to them.

\*\*\*\*\*


Full name of sole or first inventor: Keith Henry Stockman Campbell  
Inventor's signature: *Keith Henry Stockman Campbell* Date: 13.05.97  
Residence: Midlothian, Great Britain  
Citizenship: Great Britain  
Post Office Address: c/o Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS, Great Britain

\*\*\*\*\*

Full name of second joint inventor: Ian Wilmut  
Inventor's signature: *I. Wilmut* Date: May 13 1997  
Residence: Midlothian, Great Britain  
Citizenship: Great Britain  
Post Office Address: c/o Roslin Institute (Edinburgh), Roslin, Midlothian EH25 9PS, Great Britain



I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: J. W. WITHERS  
TITLE IN ORGANIZATION: COMPANY SECRETARY  
ADDRESS OF PERSON SIGNING: % ROSLIN INSTITUTE (EDINBURGH) ROSLIN MIDLOTHIAN EH25 9PS. UK.  
SIGNATURE:   
DATE: 13-5-97

00550194-032900

Docket No.: 112800.300

PATENT/OFFICIAL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :  
Keith Campbell, et al. :  
Serial No. 08/803,165 : Group Art Unit: 1632  
Filed: February 19, 1997 : Examiner: Crouch

For: Unactivated Oocytes as Cytoplast Recipients for Nuclear Transfer

ASSOCIATE POWER OF ATTORNEY

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231


Sir:

The undersigned Attorney of record hereby grants an associate power of attorney to the following registered practitioner to permit the practitioner to file related applications and to transact all business in the Patent and Trademark Office connected therewith:

Kenneth J. Meyers, Esq.  
Registration No. 25,146  
Finnegan, Henderson, Farabow, Garrett & Dunner  
1300 Eye Street, N.W., Suite 700  
Washington, D.C. 20005

Respectfully submitted,

PEPPER HAMILTON LLP

  
Gilberto M. Villacorta, Ph.D.  
Registration No. 34,038

600 Fourteenth Street, N.W.  
Washington, D.C. 20005-2004  
(202) 220-1200  
Date: 8-14-00